Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GTHX | G1 Therapeutics, Inc.

Index- P/E- EPS (ttm)-1.71 Insider Own0.90% Shs Outstand51.67M Perf Week-20.63%
Market Cap68.29M Forward P/E- EPS next Y-0.91 Insider Trans-11.97% Shs Float46.29M Perf Month-28.25%
Income-77.80M PEG- EPS next Q-0.33 Inst Own51.30% Short Float / Ratio6.33% / 3.39 Perf Quarter-51.34%
Sales89.20M P/S0.77 EPS this Y4.40% Inst Trans11.90% Short Interest2.93M Perf Half Y-55.44%
Book/sh1.11 P/B1.14 EPS next Y5.20% ROA-46.80% Target Price8.80 Perf Year-91.09%
Cash/sh1.94 P/C0.66 EPS next 5Y- ROE-143.30% 52W Range1.33 - 14.46 Perf YTD-76.61%
Dividend- P/FCF- EPS past 5Y1.00% ROI-94.60% 52W High-91.22% Beta1.89
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin94.40% 52W Low-4.51% ATR0.08
Employees170 Current Ratio4.10 Sales Q/Q300.00% Oper. Margin-74.70% RSI (14)17.27 Volatility6.65% 4.62%
OptionableYes Debt/Eq0.89 EPS Q/Q115.40% Profit Margin-87.30% Rel Volume0.53 Prev Close1.34
ShortableYes LT Debt/Eq0.89 EarningsAug 02 BMO Payout- Avg Volume864.42K Price1.27
Recom1.90 SMA20-22.19% SMA50-35.33% SMA200-63.65% Volume454,887 Change-5.22%
Date Action Analyst Rating Change Price Target Change
Jan-30-23Upgrade JP Morgan Underweight → Neutral $7 → $10
Jan-03-23Reiterated Needham Buy $32 → $31
Nov-04-21Downgrade JP Morgan Neutral → Underweight $20 → $19
Oct-15-21Resumed BTIG Research Buy $51
Sep-30-21Downgrade JP Morgan Overweight → Neutral $24 → $20
Nov-17-20Downgrade Raymond James Strong Buy → Outperform
Jun-26-20Initiated ROTH Capital Buy $55
Jan-21-20Reiterated H.C. Wainwright Buy $72 → $82
Aug-08-19Upgrade JP Morgan Neutral → Overweight
Feb-07-19Initiated B. Riley FBR Buy $55
May-18-18Reiterated Needham Buy $42 → $60
Sep-18-23 07:00AM
Sep-05-23 11:00AM
Sep-01-23 04:15PM
Aug-02-23 07:45AM
02:30PM Loading…
Jul-31-23 02:30PM
Jul-27-23 09:42AM
Jul-26-23 09:00AM
Jul-06-23 04:15PM
Jun-04-23 09:17AM
Jun-01-23 04:40PM
May-22-23 04:45PM
May-16-23 07:30AM
07:31AM Loading…
May-10-23 07:31AM
May-08-23 06:02AM
May-05-23 06:12AM
May-03-23 02:20PM
May-01-23 05:00PM
Apr-26-23 12:45PM
Apr-18-23 10:16AM
Apr-12-23 12:00PM
Apr-11-23 12:30PM
Mar-02-23 09:55PM
Mar-01-23 07:55AM
02:10PM Loading…
Feb-28-23 02:10PM
Feb-22-23 10:00AM
Feb-17-23 07:40AM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-13-23 01:33PM
Feb-09-23 08:00AM
Feb-01-23 04:46PM
Jan-11-23 07:00AM
Jan-09-23 06:30AM
Jan-04-23 11:01AM
Jan-03-23 02:00PM
Dec-07-22 06:04PM
Dec-01-22 11:41PM
Nov-27-22 10:09PM
Nov-23-22 10:30AM
Nov-22-22 04:01PM
Nov-17-22 08:12PM
Nov-03-22 08:17AM
Nov-02-22 10:19AM
Nov-01-22 05:40PM
Oct-28-22 09:40AM
Oct-26-22 09:26AM
Oct-21-22 06:42AM
Oct-19-22 12:30PM
Oct-12-22 09:40AM
Oct-10-22 06:30AM
Oct-03-22 05:00PM
Sep-10-22 08:03AM
Sep-07-22 08:00AM
Sep-06-22 07:00AM
Sep-01-22 05:22PM
Aug-26-22 09:55AM
Aug-08-22 09:55AM
Aug-04-22 04:30AM
Aug-03-22 07:45AM
Aug-01-22 05:15PM
Jul-31-22 08:03AM
Jul-28-22 10:03AM
Jul-27-22 10:02AM
Jul-25-22 06:30AM
Jul-20-22 09:00AM
Jul-13-22 10:15AM
Jul-09-22 09:54AM
Jul-01-22 05:20PM
Jun-28-22 07:30AM
Jun-13-22 07:00AM
Jun-02-22 11:00AM
Jun-01-22 04:45PM
May-24-22 08:04AM
May-20-22 10:30AM
May-18-22 10:15AM
May-07-22 10:11AM
May-04-22 07:45AM
May-02-22 05:30PM
Apr-27-22 03:03PM
Apr-21-22 08:30AM
Apr-06-22 11:30AM
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Velleca Mark A.DirectorAug 08Option Exercise0.3960,00023,156173,286Aug 10 04:11 PM
Velleca Mark A.DirectorAug 08Sale2.0060,000119,974116,000Aug 10 04:11 PM
Bailey John E. (Jack) Jr.President and CEOJul 05Sale2.452,7196,672433,563Jul 07 04:07 PM
MURDOCK TERRY LChief Operating OfficerJul 05Sale2.451,3613,33970,078Jul 07 04:08 PM
Malik RajeshChief Medical OfficerJul 05Sale2.451,3613,339136,378Jul 07 04:08 PM
Perry AndrewChief Commercial OfficerJul 05Sale2.4535587155,945Jul 07 04:08 PM
Malik RajeshChief Medical OfficerJan 05Sale5.417293,942102,739Jan 05 08:25 PM
Hanson James S.General CounselJan 05Sale5.417293,94241,087Jan 05 08:25 PM
Moses Jennifer K.CFOJan 05Sale5.417293,94257,820Jan 05 08:26 PM
MURDOCK TERRY LChief Operating OfficerJan 05Sale5.417293,94236,439Jan 05 08:26 PM
Bailey John E. (Jack) Jr.President and CEOJan 04Sale5.585,60731,262276,282Jan 05 08:23 PM
MURDOCK TERRY LChief Operating OfficerJan 04Sale5.581,6399,13837,168Jan 05 08:26 PM
Moses Jennifer K.CFOJan 04Sale5.581,6399,13858,549Jan 05 08:26 PM
Hanson James S.General CounselJan 04Sale5.581,6399,13841,816Jan 05 08:25 PM
Malik RajeshChief Medical OfficerJan 04Sale5.581,6399,138103,468Jan 05 08:25 PM
Perry AndrewChief Commercial OfficerJan 04Sale5.588204,57221,300Jan 05 08:25 PM
Bailey John E. (Jack) Jr.President and CEOJan 03Sale5.8532,019187,452281,889Jan 05 08:23 PM
Malik RajeshChief Medical OfficerDec 15Option Exercise0.3014,0004,20087,207Dec 16 04:12 PM
Velleca Mark A.DirectorOct 18Option Exercise0.3915,0005,850131,000Oct 20 04:05 PM
Velleca Mark A.DirectorOct 18Sale11.7015,000175,490116,000Oct 20 04:05 PM